Roche’s new vaginitis PCR test is FDA-cleared, but the real commercial test starts inside laboratories
Roche’s cobas BV/CV assay gains FDA clearance for combined BV and Candida testing, setting up a 2026 U.S. laboratory launch.
Medical Devices & Diagnostics
Pharma & Biotech
Roche ends two Huntington’s disease programmes after separate clinical setbacks
Roche Holding AG has discontinued development of tominersen and RG6496, removing two investigational huntingtin-lowering medicines from its neurology pipeline after separate setbacks emerged almost simultaneously. The Phase 2 GENERATION HD2 trial showed that tominersen lowered important biological markers but did not meaningfully slow clinical decline, while the Phase 1 POINT-HD study of RG6496 was halted
Pharma & Biotech
Teva wants a slice of Roche’s CHF 7bn Ocrevus franchise, but PB018 still has a long road ahead
Teva gains broad rights to PB018 as Polpharma Biologics advances an Ocrevus biosimilar into clinical development for multiple sclerosis.
Medical Devices & Diagnostics
Could Beckman Coulter’s Access p-Tau217 test make Alzheimer’s diagnosis faster and cheaper?
Beckman Coulter Diagnostics has secured European clearance for its automated Access p-Tau217 blood test, potentially widening access to Alzheimer’s biomarker testing while raising questions about reimbursement, intermediate results and clinical interpretation.
Pharma & Biotech
Otsuka’s Astex secures $515m Roche deal for cell-cycle breast cancer candidates
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Pharma & Biotech
Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?
Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.
Pharma & Biotech
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Pharma & Biotech
Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Medical Devices & Diagnostics
What Roche’s $1.05bn PathAI move reveals about the future of pathology labs
Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.
Pharma & Biotech
Can Genentech’s Enspryng become the first approved treatment for MOGAD after the Phase III METEOROID win?
Genentech’s Enspryng cut MOGAD relapse risk by 68% in Phase III. Read what the data could mean for regulators, clinicians, and the rare disease market.